# US 2020/0392250 A1 · Hexokinase 2-specific inhibitor in acute central nervous system injury disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392250 A1
- Document ID: US20200392250A1
- Status: Published application
- Kind: A1
- Application number: 16/488,011
- Filed: 2018-02-06
- Published: 2020-12-17
- Earliest claimed: 2017-02-23
- Assignees: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
- Applicants: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
- Inventors: Guangmei YAN; Wei YIN; Yuan LI; Bingzheng LU; Longxiang SHENG
- Web page: https://patentgrep.com/patent/US20200392250A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C07K 16/40: against enzymes
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.

## Claims

### Claim 1

A method for treatment of acute central nervous system injury comprising administering to a subject a pharmaceutically effective amount of a hexokinase 2-specific inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hexokinase 2-specific inhibitor is a hexokinase 2 antibody or a fragment thereof, or siRNA, shRNA, miRNA or a modification thereof that interferes with mRNA of hexokinase 2.

### Claim 3 (depends on 2)

The method of claim 2, wherein the hexokinase 2 antibody exists in a form of an amino acid sequence encoding the antibody, a nucleotide sequence encoding the antibody, or an expression vector comprising the amino acid or nucleotide sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein the hexokinase 2 antibody exists in a form of a fusion protein contained in an expression vector or host cell.

### Claim 5 (depends on 3)

The method of claim 3, wherein the fragment of the antibody is Fab, Fab′, (Fab′)2 or Fv.

### Claim 6 (depends on 2)

The method of claim 2, wherein the siRNA, shRNA, miRNA or a modification thereof is contained in a certain vector.

### Claim 7 (depends on 1)

The method of claim 1, wherein the acute central nervous system injury is an encephalon/spinal damage caused by any of a group consisting of acute spinal injury, brain trauma, retinal damage, hypoxic brain injury, acute ischemic brain injury, ischemic stroke, hypoxic stroke, neonatal hypoxic ischemic encephalopathy, toxic encephalopathy, acute cerebral infarction, lacunar infarction, transient ischemic attack, severe craniocerebral injury, cerebrospinal surgery and encephalon/spinal radiotherapy.

### Claim 8

A method for treatment of acute central nervous system injury comprising administering to a subject a pharmaceutically effective amount of a composition comprising hexokinase 2-specific inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the hexokinase 2-specific inhibitor is a hexokinase 2 antibody or a fragment thereof, or siRNA, shRNA, miRNA or a modification thereof that interferes with mRNA of hexokinase 2.

### Claim 10 (depends on 8)

The method of claim 8, wherein the composition further comprises one or more compound selected from a group consisting of 2-deoxyglucose, lonidamine, bromopyruvic acid, glucose 6-phosphate, Imatinib, 5-thio-glucose and methyl jasmonate.
